10 Results for "

α5β3γ2

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "α5β3γ2" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-120051
CAS No.: 1398496-82-6
Purity:  98.40%
Synonyms: S44819; Egis-13529
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Afizagabar (S44819) is a first-in-class, competitive, and selective antagonist at the GABA-binding site of the α5-GABAAR, with an IC50 of 585 nM for α5β2γ2 and a Ki of 66 nM for α5β3γ2. Afizagabar enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-100370
CAS No.: 342652-67-9
Purity:  99.71%
Target:  

GABA Receptor

Research Areas:  

Cancer

MRK-016 is a selective, orally bioavailable inverse agonist of GABAA α5 receptor, with an EC50 of 3 nM for GABAA α5, and Kis of 0.83, 0.85, 0.77 and 1.4 nM for human GABAA α1β3γ2, GABAA α2β3γ2, GABAA α3β3γ2, and GABAA α5β3γ2, respectively; MRK-016 also readily penetrates the CNS.
loading...
    loading...
Cat. No.: HY-132806
CAS No.: 2230009-48-8
Purity:  99.93%
Synonyms: RG-7816; RO-7017773
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Alogabat is a positive allosteric modulator (PAM) and agonist (Ki <100 nM) of the GABAA α5 receptor, targeting the α5β3γ2 subunit with a Ki of 8.7 nM. Alogabat increases the expression level of α5β3γ2 in oocytes (1.97-fold). GABAA has been implicated in cognitive impairment associated with central nervous system (CNS) disorders, brain cancer (including brain tumors such as medulloblastoma), and can be used in the study of mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer treatment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X, Rett syndrome, obsessive-compulsive behavior, and substance addiction .
loading...
    loading...
Cat. No.: HY-15831
CAS No.: 1213669-91-0
Purity:  99.71%
L-838417-d9 is the deuterium labeled L-838417 (HY-W009009). L-838417 is a selective partial agonist at the α2, α3 and α5 subtypes of the GABAA receptor and an antagonist at the α1, with binding Ki values of 0.79 nM, 0.67 nM, 1.67 nM, 267 nM, 2.25 nM and 2183 nM for α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2, α5β3γ2 and α6β3γ2. L-838417 has anti-anxiety activity .
loading...
    loading...
Cat. No.: HY-W009009
CAS No.: 286456-42-6
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

L-838417 is a selective partial agonist at the α2, α3 and α5 subtypes of the GABAA receptor and an antagonist at the α1, with binding Ki values of 0.79 nM, 0.67 nM, 1.67 nM, 267 nM, 2.25 nM and 2183 nM for α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2, α5β3γ2 and α6β3γ2. L-838417 has anti-anxiety activity .
loading...
    loading...
Cat. No.: HY-107489
CAS No.: 883093-10-5
Purity:  99.30%
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

RO 4938581 is a potent and selective GABAA α5 inverse agonist, with a Ki of 4.6 nM for GABAA α5β3γ2a, and shows a lower affinity at α1β3γ2a, α2β3γ2a, α3β3γ2a (Ki, 174, 185, 80 nM, respectively); RO 4938581 is used in the research of cognitive dysfunction.
loading...
    loading...
Cat. No.: HY-103521
CAS No.: 355022-97-8
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Anxiolytic/nonsedative agent-1 (compound 2b) is a potent and selective GABAA agonist. Anxiolytic/nonsedative agent-1 shows appreciable affinity for the BzR in bovine brain membranes with Kis of 14, 121, 239 nM for α1β2γ2, α2β2γ2, α5β3γ2, respectively. Anxiolytic/nonsedative agent-1 shows α2 selective efficacy in vitro and anxioselective effects in vivo .
loading...
    loading...
Cat. No.: HY-W009009R
CAS No.: 286456-42-6
Research Areas:  

Neurological Disease

L-838417 (Standard) is the analytical standard of L-838417 (HY-W009009). This product is intended for research and analytical applications. L-838417 is a selective partial agonist at the α2, α3 and α5 subtypes of the GABAA receptor and an antagonist at the α1, with binding Ki values of 0.79 nM, 0.67 nM, 1.67 nM, 267 nM, 2.25 nM and 2183 nM for α1β3γ2, α2β3γ2, α3β3γ2, α4β3γ2, α5β3γ2 and α6β3γ2. L-838417 has anti-anxiety activity .
loading...
    loading...
Cat. No.: HY-189454
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

ETK-III-9 is an orally active and blood-brain barrier-penetrant GABAA receptor ligand. ETK-III-9 displaces 3H-flunitrazepam at the benzodiazepine site of GABAA receptors, with stronger interactions at α3β3γ2 and α5β3γ2 subtypes. ETK-III-9 exhibits a target IC50 value of 97.8 nM for rat α3/α5-containing GABAA receptors and 7.6 nM for rat α5β3γ2 subtypes. ETK-III-9 is used in anxiety research .
loading...
    loading...
Cat. No.: HY-107489R
CAS No.: 883093-10-5
Research Areas:  

Neurological Disease

RO 4938581 (Standard) is the analytical standard of RO 4938581 (HY-107489). This product is intended for research and analytical applications. RO 4938581 is a potent and selective GABAA α5 inverse agonist, with a Ki of 4.6 nM for GABAA α5β3γ2a, and shows a lower affinity at α1β3γ2a, α2β3γ2a, α3β3γ2a (Ki, 174, 185, 80 nM, respectively); RO 4938581 is used in the research of cognitive dysfunction.
loading...
    loading...